Katadol Capsule contains Flupirtine 100 mg, a non-opioid analgesic primarily used for the management of moderate to severe pain. Flupirtine acts as a selective neuronal potassium channel opener and NMDA receptor antagonist, providing analgesic and muscle-relaxant effects without the typical side effects associated with opioids or NSAIDs. Katadol is indicated for acute and chronic pain conditions including musculoskeletal pain, postoperative pain, and neuropathic pain. It is particularly useful in patients where conventional analgesics are contraindicated or poorly tolerated. The onset of action is typically within 30 to 60 minutes, with effects lasting up to 6 hours. Katadol should be administered orally, with dosage and duration tailored to the individual patient’s clinical condition and response. Caution is advised in patients with hepatic impairment, as Flupirtine has been associated with rare but serious hepatotoxicity; liver function monitoring is recommended during prolonged therapy. It is contraindicated in patients with severe liver disease, porphyria, or hypersensitivity to Flupirtine. Common adverse effects include dizziness, nausea, and fatigue. Katadol Capsule should be used under medical supervision, adhering strictly to prescribed dosages to minimize risks and ensure therapeutic efficacy.